Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacogenomics' Reality Check

This article was originally published in Start Up

Executive Summary

Pharmacogenomics is making its way into the infrastructure of clinical medicine. Large companies are discussing pharmacogenomics at the board level, and issuing top-down pronouncements about it. It is also entering the vocabulary of drug testing teams; pharmacogenomics is, for instance, being applied to traditional pharmacogenetic drug metabolism tests. The technology will almost certainly impact drug discovery. Knowing the genetic variability of a target can help a drug developer choose the best candidate from among three or four leads early in the game. But cost-effective enabling technologies do not yet exist. Most sorely missed are cost-effective, high-throughput genotyping methods. For now, companies are banking samples of patients' DNA and developing genetic tests to accompany drugs in clinical trials and on the market. Even as tool providers work to overcome technology hurdles, drug companies unquestionably remain worried about the possibility that pharmacogenomics information could limit the market potential of their products. Nevertheless, the buy-in may well come--surprisingly--from marketing people.
Advertisement

Related Content

Pharmacogenomics: Promises and Problems
Why Don't Big Pharmas Buy Pharmacogenomics?
Gentris Corp.
The Population Genetics Equation: Data + Product Focus = Funding

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC090215

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel